Document:

exv10w2

Exhibit 10.2

EXECUTION VERSION

FIRST AMENDMENT TO

EXECUTIVE RETENTION AGREEMENT

     This FIRST AMENDMENT TO EXECUTIVE RETENTION AGREEMENT (this “Amendment”) is made and entered
into as of the 18th day of June, 2009 (the “Amendment Date”), by and between Cornerstone BioPharma,
Inc., a Delaware corporation (the “Company”), and Craig A. Collard (the “Executive”). The Company
and the Executive may be referred to herein as the “parties.”

W I T N E S S E T H :

     WHEREAS, the Company and the Executive entered into an Executive Retention Agreement as of
February 8, 2006 (the “Executive Retention Agreement”);

     WHEREAS, effective October 31, 2008, Neptune Acquisition Corp., a Delaware corporation and a
wholly owned subsidiary of Critical Therapeutics, Inc. (“Transitory Subsidiary”), merged with and
into Cornerstone BioPharma Holdings, Inc., a Delaware corporation and the parent company of the
Company (“CBHI”), as contemplated by the Agreement and Plan of Merger (the “Merger Agreement”),
dated as of May 1, 2008, as amended, by and among Critical Therapeutics, Inc., Transitory
Subsidiary and CBHI (the “Merger”);

     WHEREAS, by virtue of the Merger, the Company became an indirect wholly owned subsidiary of
Critical Therapeutics, Inc., which subsequently changed its name to Cornerstone Therapeutics Inc.
(“Cornerstone Therapeutics”), and, in accordance with the Merger Agreement, all stock options held
by the Executive that were exercisable for CBHI’s common stock were assumed by Cornerstone
Therapeutics and became options to acquire Cornerstone Therapeutics common stock; and

     WHEREAS, the Company and the Executive desire to amend the Executive Retention Agreement to
immediately accelerate vesting of certain Cornerstone Therapeutics stock, stock options, benefits
and otherwise held by or accruing to the Executive contemporaneously with a change in control of
Cornerstone Therapeutics.

     NOW, THEREFORE, in consideration of the premises set forth above and the mutual terms and
conditions set forth below and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Company and the Executive agree as follows:

     1. Effective as of the Amendment Date, Section 1.1.(a) of the Executive Retention Agreement
shall be deleted and the following inserted in lieu thereof:

               “(a) an acquisition by an individual, entity or group (within the meaning of Section 13(d)(3)
or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) unrelated to
Cornerstone Therapeutics or any of its subsidiaries (a “Third Party”) of beneficial ownership of
any capital stock of Cornerstone Therapeutics if, as a result of such acquisition, such Third Party
becomes the beneficial owner (within the meaning of Rule

 

 

13d-3 promulgated under the Exchange Act) of more than 50% of the combined voting power of the
then-outstanding securities of Cornerstone Therapeutics entitled to vote generally in the election
of directors.”

     2. Effective as of the Amendment Date, the Executive Retention Agreement shall be amended to
include a new Section 4.5 as follows:

         “4.5 Change in Control. Notwithstanding the above, immediately prior to a Change in
Control, any of the Executive’s unvested rights in Cornerstone Therapeutics Inc., a Delaware
corporation and, effective October 31, 2008, the ultimate parent company of the Company
(“Cornerstone Therapeutics”), stock, stock options, benefits or otherwise that are currently
unvested and would have become vested through the passage of time shall immediately vest. The
parties acknowledge and agree that the rights contained in this Section 4.5 shall be in addition
to, and not restrictive of, any accelerated vesting provided under any equity incentive plan in
which the Executive participates or any equity award granted to the Executive thereunder.
Notwithstanding the foregoing, this Section 4.5 shall not apply to any grants of stock, stock
options, benefits or otherwise made to the Executive on or after May 28, 2009.”

     3. Effective as of the Amendment Date, Section 7 of the Executive Retention Agreement shall be
deleted and the following inserted in lieu thereof:

     “7. Notice. All notices, instructions and other communications given hereunder or in
connection herewith shall be in writing. Any such notice, instruction or communication shall be
sent either (i) by registered or certified mail, return receipt requested, postage prepaid, or (ii)
prepaid via a reputable nationwide overnight courier service, in each case addressed to the Company
at 1255 Crescent Green Drive, Suite 250, Cary, NC 27518, and to the Executive at the Executive’s
address indicated on the signature page of this Agreement (or to such other address as either the
Company or the Executive may have furnished to the other in writing in accordance herewith). Any
such notice, instruction or communication shall be deemed to have been delivered five business days
after it is sent by registered or certified mail, return receipt requested, postage prepaid, or one
business day after it is sent via a reputable nationwide overnight courier service. Either party
may give any notice, instruction or other communication hereunder using any other means, but no
such notice, instruction or other communication shall be deemed to have been duly delivered unless
and until it actually is received by the party for whom it is intended.”

     4. Except as hereby amended, the terms and conditions of the Executive Retention Agreement as
in effect immediately prior to this Amendment remain in full force and effect.

[signature page follows]

2

 

[Signature Page to First Amendment to Executive Retention Agreement]

     IN WITNESS WHEREOF, this Amendment has been duly executed as of the day and year first set
forth above.

	 	 	 	 	 
	 	CORNERSTONE BIOPHARMA, INC.	 
	 
	 	 	 
	 	By:  	                           /s/ David Price
 	 
	 	 	Name:  	David Price 	 
	 	 	Title:  	Executive Vice President, Finance,

and Chief Financial Officer 	 
	 
	 	EXECUTIVE	 
	 
	 
	 	/s/ Craig A. Collard 

Name: Craig A. Collard	 	 
	 
	 	 	 	 
	 
	 	Address:	 	 
	 
	 	107 Trellingwood Drive	 	 
	 
	 	Morrisville, NC 27560	 	 

ACKNOWLEDGED AND AGREED:

CORNERSTONE THERAPEUTICS INC.

	 	 	 	 	 
	By:

	 	/s/ David Price 

Name: David Price	 	 
	 

	 	Title: Executive Vice President, Finance,

          and Chief Financial Officerexv10w3

Exhibit 10.3

EXECUTION VERSION

FIRST AMENDMENT TO

EXECUTIVE EMPLOYMENT AGREEMENT

     This FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered
into as of the 12th day of June, 2009 (the “Amendment Date”), by and between Cornerstone BioPharma,
Inc., a Delaware corporation (the “Company”), and Brian Dickson, M.D. (the “Executive”). The
Company and the Executive may be referred to herein as the “parties.”

W I T N E S S E T H :

     WHEREAS, the Company and the Executive entered into an Executive Employment Agreement
effective as of March 1, 2006 (the “Executive Employment Agreement”) and a Proprietary Information,
Inventions, Non-competition, and Non-solicitation Agreement effective as of the same date (the
“Proprietary Information Agreement”), the terms of which were expressly made a part of the
Executive Employment Agreement;

     WHEREAS, the Company and the Executive had previously entered into an Agreement Regarding
Employment, Employee Duties, Ownership of Employee Developments, and Confidentiality dated as of
May 2005 (the “Duties Agreement”), which provided in Section 2.2 thereof for the accelerated
vesting of all of the Executive’s then unvested stock, stock options, benefits and otherwise upon
the occurrence of any change in control, defined therein as the transfer of greater than 50% of the
common ownership of the group to an unrelated third party;

     WHEREAS, the Executive Employment Agreement and the Proprietary Information Agreement
contained merger and integration clauses, which had the legal effect of superseding the Duties
Agreement in its entirety, including Section 2.2 thereof;

     WHEREAS, the parties acknowledge and agree that, notwithstanding the merger and integration
clauses contained in the Executive Employment Agreement and the Proprietary Information Agreement,
it was the intention of the parties that Section 2.2 of the Duties Agreement would continue in full
force and effect; that Section 2.2 would not be terminated by the Executive Employment Agreement or
the Proprietary Information Agreement; and that the accelerated vesting provided by Section 2.2
would be in addition to, and not restrictive of, any accelerated vesting provided under any equity
incentive plan in which the Executive participates or any equity award granted to the Executive
thereunder;

     WHEREAS, effective October 31, 2008, Neptune Acquisition Corp., a Delaware corporation and a
wholly owned subsidiary of Critical Therapeutics, Inc. (“Transitory Subsidiary”), merged with and
into Cornerstone BioPharma Holdings, Inc., a Delaware corporation and the parent company of the
Company (“CBHI”), as contemplated by the Agreement and Plan of Merger (the “Merger Agreement”),
dated as of May 1, 2008, as amended, by and among Critical Therapeutics, Inc., Transitory
Subsidiary and CBHI (the “Merger”);

 

 

     WHEREAS, by virtue of the Merger, the Company became an indirect wholly owned subsidiary of
Critical Therapeutics, Inc., which subsequently changed its name to Cornerstone Therapeutics Inc.
(“Cornerstone Therapeutics”), and, in accordance with the Merger Agreement, all stock options held
by the Executive that were exercisable for CBHI common stock were assumed by Cornerstone
Therapeutics and became options to acquire Cornerstone Therapeutics common stock;

     WHEREAS, following the Merger, the Company and the Executive desire to amend the Executive
Employment Agreement to reflect the parties’ intentions regarding accelerated vesting of
Cornerstone Therapeutics stock, stock options, benefits and otherwise held by or accruing to the
Executive in the event of a change in control of Cornerstone Therapeutics; and

     WHEREAS, the Company has recently hired a Vice President, Scientific Affairs, reporting to the
President/Chief Executive Officer, with responsibility for performing certain development,
regulatory, quality, compliance and technical affairs duties as are customarily performed by
individuals filling such positions within the pharmaceutical industry, and the Company and the
Executive desire to clarify the Executive’s duties and responsibilities to ensure effective
coordination between the Executive and the Vice President, Scientific Affairs, in areas of joint or
overlapping responsibility.

     NOW, THEREFORE, in consideration of the premises set forth above and the mutual terms and
conditions set forth below and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Company and the Executive agree as follows:

     1. Effective as of the Amendment Date, Section 2 of the Executive Employment Agreement shall
be deleted and the following shall be inserted in lieu thereof:

          2. Duties.

          (a) The Executive shall faithfully perform all duties of the Company related to
the position or positions held by the Executive, including but not limited to all
duties set forth in this Agreement and/or in the Bylaws of the Company related to
the position or positions held by the Executive and all additional duties that are
prescribed from time to time by the Board of Directors of the Company (the “Board”)
or other designated officers of the Company. Among other duties, the Executive shall
be responsible for performing all development, regulatory, quality, compliance and
technical affairs duties as are customarily performed by chief medical officers of
companies within the pharmaceutical industry. In performing such development,
regulatory, quality, compliance and technical affairs duties, the Executive shall
cooperate with the Vice President, Scientific Affairs in areas of joint or
overlapping responsibility. In the event that there is any question whether the
Executive or the Vice President, Scientific Affairs should be responsible for
particular duties, the Executive shall refer the matter to the President and Chief
Executive Officer for decision.

2

 

          (b) The Executive shall devote the Executive’s full time and attention to the
performance of the Executive’s duties and responsibilities on behalf of the Company
and in furtherance of its best interests; provided, however, that the Executive,
subject to the Executive’s obligations hereunder, shall also be permitted to make
personal investments, perform reasonable volunteer services and, with the prior
consent of the Company, serve on outside boards of directors for non-profit
corporations. The Executive shall comply with all Company policies, standards, rules
and regulations (the “Company Policies”) and all applicable government laws, rules
and regulations that are now or hereafter in effect. The Executive acknowledges
receipt of copies of all written Company Policies that are in effect as of the date
of this Agreement.

     2. Effective as of the Amendment Date, the Executive Employment Agreement shall be amended to
include a new Section 4.(h) as follows:

     “4.(h) Change in Control. Immediately prior to a Change in Control,
any of the Executive’s unvested rights in Cornerstone Therapeutics Inc., a Delaware
corporation and, effective October 31, 2008, the ultimate parent company of the
Company (“Cornerstone Therapeutics”), stock, stock options, benefits or otherwise
that are currently unvested and would have become vested through the passage of time
shall immediately vest. For purposes of this agreement, a Change in Control is
defined as the acquisition by an individual, entity or group (within the meaning of
Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”)) unrelated to Cornerstone Therapeutics or any of its subsidiaries (a
“Third Party”) of beneficial ownership of any capital stock of Cornerstone
Therapeutics if, as a result of such acquisition, such Third Party becomes the
beneficial owner (within the meaning of Rule 13d-3 promulgated under the Exchange
Act) of more than 50% of the combined voting power of the then-outstanding
securities of Cornerstone Therapeutics entitled to vote generally in the election of
directors. The parties acknowledge and agree that the rights contained in this
Section 4.(h) shall be in addition to, and not restrictive of, any accelerated
vesting provided under any equity incentive plan in which the Executive participates
or any equity award granted to the Executive thereunder. Notwithstanding the
foregoing, this Section 4.(h) shall not apply to any grants of stock, stock options,
benefits or otherwise made to the Executive on or after May 28, 2009.”

     3. Except as hereby amended, the terms and conditions of the Executive Employment Agreement as
in effect immediately prior to this Amendment remain in full force and effect.

[signature page follows]

3

 

[Signature Page to First Amendment to Executive Employment Agreement]

     IN WITNESS WHEREOF, this Amendment has been duly executed as of the day and year first set
forth above.

	 	 	 	 	 
	 	CORNERSTONE BIOPHARMA, INC.

 	 
	 	By:  	/s/ Craig A. Collard
 	 
	 	 	Name:  	Craig A. Collard 	 
	 	 	Title:  	President and Chief Executive Officer 	 
	 
	 	EXECUTIVE

 	 
	 	 	/s/ Brian Dickson
 	 
	 	 	Name:  	Brian Dickson, M.D. 	 
	 	 	 
	 

ACKNOWLEDGED AND AGREED:

CORNERSTONE THERAPEUTICS INC.

	 	 	 	 	 	 	 
	By:	 	/s/ Craig A. Collard	 	 
	 	 	 	 	 
	 

	 	Name:
	 	Craig A. Collard	 	 
	 

	 	Title:
	 	President and Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00159-of-00352.parquet"}]]